Everest Medicines announced that under an amended license agreement with Spero Therapeutics, the relevant patents for SPR206 will be assigned to Everest in Greater China, South Korea and certain Southeast Asian countries. The companies announced in January 2019 a collaboration agreement to develop, manufacture and commercialize SPR206 in the Territory.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.4 HKD | +3.87% |
|
+5.15% | -2.39% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.39% | 838M | |
+6.96% | 101B | |
+8.29% | 42.63B | |
-11.09% | 33.5B | |
+82.32% | 29.77B | |
-11.82% | 16.14B | |
+1.39% | 14.31B | |
-12.13% | 11.55B | |
+176.65% | 10.53B | |
+6.74% | 9.2B |
- Stock Market
- Equities
- 1952 Stock
- News Everest Medicines Limited
- Everest Medicines Announces Amended Agreement with Spero Therapeutics